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Objectives: Moldova is a country where expenditure on pharmaceuticals is already 
very high and exceeds several times the prices in the region. Drugs expenditure 
represents 70% of direct health expenditure of a household and is the main factor 
that reduces the financial protection of health care services. The objective of the 
study was to assess affordability of reimbursement medicines and to evaluate the 
National Health Insurance Company (NHIC) impact on ensuring economic accessibil-
ity. MethOds: To determine the affordability of medicines was used the methodology 
recommended by the World Health Organization. Have been analyzed data concern-
ing price of drugs, the amounts paid by patients and the amounts paid by the NHIC 
for partially reimbursed drugs for 5 years (2008-2012). Was calculated: the median 
price for each drug international common name dependent’s on strength; duration of 
treatment and number of units needed for treatment (for chronic disease); number of 
working days required for a treatment cure depending on minimum wage and aver-
age wage in economy. Available treatment is considered, the cost of which is 1 or less 
than the cost of one working day. Based on these results has been also determined 
the impact of the NHIC. Results: Number of economically accessible reimbursed 
drugs depending on minimum wage was: 2008-24 (42%), 2009-34 (60%), 2010-43 (53%), 
2011-48 (58%), and 2012-71 (86%); depending on average wage in economy: 2008-50 
(87%), 2009-50 (87%), 2010-66 (81%), 2011-73 (88%), and 2012-77(94%). The average num-
ber of working days compensated by NHIC based on the minimum wage: 2008-6.23, 
2009-3.5, 2010-3.7, 2011-2.92, and 2012-1.03; based on average wage in economy: 2008-
0.98, 2009-0.76, 2010-0.75, 2011-0.55, and 2012-0.38. cOnclusiOns: Compensation 
of drugs by NHIC, doesn’t significantly affect the affordability of reimbursement 
medicines. Patients feels no real benefit from NHIC, drugs expenditure within the 
households practically remain unchanged even if it get reimbursed medicines.
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Objectives: To assess the methodological quality of economic evaluations included 
in Belgian reimbursement applications for Class 1 drugs. MethOds: For 19 reim-
bursement applications submitted during 2011 and Spring 2012, a descriptive analy-
sis assessed the methodological quality of the economic evaluation, evaluated the 
assessment of that economic evaluation by the Drug Reimbursement Committee 
and the response to that assessment by the company. Compliance with methodo-
logical guidelines issued by the Belgian Healthcare Knowledge Centre was assessed 
using a detailed checklist of 23 methodological items. The rate of compliance was 
calculated based on the number of economic evaluations for which the item was 
applicable. Results: Economic evaluations tended to comply with guidelines 
regarding perspective, target population, subgroup analyses, comparator, use of 
comparative clinical data and final outcome measures, calculation of costs, incre-
mental analysis, discounting and time horizon. However, more attention needs to 
be paid to the description of limitations of indirect comparisons, the choice of an 
appropriate analytic technique, the expression of unit costs in values for the cur-
rent year, the estimation and valuation of outcomes, the presentation of results of 
sensitivity analyses, and testing the face validity of model inputs and outputs. Also, 
a large variation was observed in the scope and depth of the quality assessment by 
the Drug Reimbursement Committee. cOnclusiOns: Although general guidelines 
exist, pharmaceutical companies and the Drug Reimbursement Committee would 
benefit from the existence of a more detailed checklist of methodological items that 
need to be reported in an economic evaluation.
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Objectives: In the CZ, orphan drugs so-called highly innovative drugs first enter 
a temporary reimbursement period of three years. Having proven their cost-effec-
tiveness they later become permanently reimbursed. The objective of the study 
was to determine how successfully orphan drugs enter the database of reimbursed 
drugs. MethOds: The EMA list of orphan drugs was compared to the Czech data-
base of reimbursed drugs to the date of 1-Jul-2013. For each detected drug the date 
of entering the database was found. In drugs reimbursed after 2008, submissions 
of cost effectiveness analyses were recorded. Although CZ has no willingness to 
pay threshold, interpretation of cost effectiveness analyses results could improve 
the process of HTA of drugs. Results: To the date of 1-Apr-2013 the EMA has 
registered 65 orphan drugs. Out of these, 28 have been assigned a maximum and 
reimbursement price in the CZ. To this date, 27 drugs have not applied for reimburse-
ment price. Starting from 2008, 30 drugs have applied: in 20 products the decision 
is legally effective, in 2 cases only hospital use has been approved, in 7 cases (3 
appeals, 4 unfinished proceedings) the proceedings are still in process and in one 
case the application was withdrawn. In about a third of cases a cost effectiveness 
analysis was submitted and accepted by SUKL. The upper limit of the ICER of the 
submitted analyses exceeds by far the cost-effectiveness level recommended by the 
WHO. cOnclusiOns: The results imply that in almost in all cases the submitted 
applications for maximum and reimbursement price are approved by SUKL. In some 
cases, however, the health insurance companies hinder reimbursement of drugs 
by filing an appeal. However, the assessment of cost effectiveness of drugs should 
be performed at an earlier level – during the administrative proceedings. This calls 
for necessary emphasis on health technology assessment.
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age including clinical and health economic data and takes on average more than 
two years. In the UK the process is largely based on three different PCT payment 
and the various NHS value for money mechanisms combined with procurement 
systems. The value-based pricing system might change the current situation. Finally, 
in the US CPT codes are similarly being applied as DRG codes in Germany with 
a different pathway of application. In comparison the health economic evidence 
plays a larger role in the UK, even though (still) not in a systematic manner as for 
pharmaceuticals. The clinical evidence plays an important role in all countries, 
however it was identified that for diagnostic tests the access routes and especially 
the coding process is more dependent on consistency on applicability of existing 
codes and technology argumentation. cOnclusiOns: In the different countries 
the evidence base for market access and reimbursement pathways for diagnostics 
differs significantly. Instead, having a unified approach might ease a value based 
market access argumentation for diagnostics.
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Objectives: Considerations beyond (cost-) effectiveness are increasingly important 
in reimbursement decision-making. We investigated the importance of disease sever-
ity relatively to other decision criteria in drug reimbursement decision-making in four 
European countries. MethOds: The importance of disease severity and its operation-
alization was assessed in Belgium, France, The Netherlands and Sweden. We investi-
gated scientific literature, policy documents, reimbursement reports, and conducted 
three interviews in each country (four in The Netherlands) with policymakers involved 
in drug reimbursement. Results: All interviewees acknowledged that disease sever-
ity is, especially in case of high severity, an important criterion while considering 
a drug’s (cost-) effectiveness. However, its relative importance compared to other 
decision criteria remains implicit in the decision-making process. Although rarity of 
the disease is not a criterion as such, interviewees indicated difficulties in separating 
rarity from severity and the availability of alternative treatments. Only Belgium and 
France explicitly show societal willingness to pay by using reimbursement levels 
depending on the severity of the disease. In Sweden, ‘need and solidarity’ is one 
of the three prioritizing principles. The Netherlands is the only country that quan-
titatively operationalized disease severity using the proportional shortfall method 
and suggesting a cost-effectiveness threshold range depending on disease severity 
(which was never formalised by the minister). Although interviewees acknowledged 
that quantitative information, besides a qualitative description of the disease, may 
provide additional decision information, none of them considered such information 
to be of decisive importance. cOnclusiOns: Disease severity is, especially in case 
of high severity, an important decision criterion in all four countries. However, all 
countries seem to struggle in making its actual role explicit. The operationalization 
differs across countries. While Belgium and France are most explicit by using the 
severity of the disease in setting reimbursement levels, all countries could improve 
transparency of its actual importance relatively to other decision criteria.
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Objectives: To evaluate the clinical and health economic evidence requirements 
for obtaining statutory health insurance coverage for innovative medical devices 
(MDs) in Germany. MethOds: We have assessed the requirements for innovative 
MDs in Germany according to the available reimbursement pathways and grouped 
them by the application setting as this had a significant impact on the research 
question. Results: According to the German statutory rules in the inpatient care 
setting (reservation of prohibition; ‘Verbotsvorbehalt’) all innovative MDs can be 
applied once they have received marketing approval for Germany (CE mark) whereas 
a positive voting from the federal joint committee is required before MDs can be 
applied in the outpatient setting (reservation of authorization; ‚Erlaubnisvorbehalt’). 
The reimbursement coverage in the inpatient setting depends on the available cod-
ing and grouping mechanisms that define specific diagnoses related groups and 
their reimbursement value. If this value is not adequate or an adequate coding/
grouping is not possible specific applications can be made, that require no specific 
clinical and health economic evidence; only a detailed (additional) cost estimation 
of the new procedure and a rationale of the innovative character are required. In 
contrast the outpatient reimbursement of the statutory health insurance shows 
very strict requirements as a detailed clinical evidence reporting (e.g. randomized-
controlled trials) and a full health economic evaluation (e.g. cost-effectiveness and 
budget impact assessment) need to be provided for obtaining reimbursement cov-
erage. There are recent political streams that claim that the regulatory and reim-
bursement process of MDs should be adapted comparable to the more restrictive 
regulations for pharmaceuticals which might have a major impact on the evidence 
requirements for the inpatient sector. cOnclusiOns: Currently MDs applied in the 
inpatient setting require no specific evidence whereas strong clinical and health 
economic evidence is required for MDs applied in the outpatient setting.
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take into account confidential discounts under patient access schemes. Finally, 
the threshold probability of cost effectiveness seems to lie between 30% and 60%.
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Objectives: Multi criteria decision analysis (MCDA) aims to support decision-mak-
ing where decisions are based on multiple criteria. In disciplines like engineering 
and environmental policy, MCDA is widely accepted and routinely used. The use of 
MCDA in HTA priority setting and reimbursement decisions is growing, but mostly 
limited to research projects. A factor that might influence acceptance is a perceived 
difficulty to value an MCDA’s outcome when its inputs and outputs contain uncer-
tainties. When this is the case, decision makers might not feel confident in accept-
ing or rejecting its outcome. The objective of this study is to systematically review 
how parameter uncertainty is taken into account in value-based MCDA methods 
in general, and to discuss which of the approaches is appropriate for the setting of 
reimbursement decision making in health care. MethOds: A systematic literature 
review was conducted using the Scopus database. Found abstracts were categorized 
by MCDA method used. Then, themes and families of methods were identified by 
two independent reviewers. Selected full text articles were read to identify methodo-
logical details. Results: The search strategy identified 635 abstracts, mostly from 
engineering and environmental journals and only 1.6% in health journals. Identified 
themes were fuzzy set theory (n= 223), probabilistic framework (n= 68), deterministic 
sensitivity analysis (n= 140), Dempster-Shafer theory (n= 14), Bayesian framework 
(n= 7) and Grey theory (n= 8). A large number of papers considered the Analytic 
Hierarchy Process in combination with fuzzy set theory (n= 155). cOnclusiOns: 
In the health literature there is little attention for parameter uncertainty. Methods 
to deal with parameter uncertainty in MCDA must strike a balance between com-
prehensibility and understandability. Several complex methods are developed for 
parameter uncertainty, but there seems to be a gap between the theory and the 
implementation of those methods. For simple applications, methods like deter-
ministic sensitivity analysis are likely to be sufficient.
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Objectives: To investigate quantitatively, if and to which extent the German 
Arzneimittelmarkt-Neuordnungs-Gesetz (AMNOG) delays market access of phar-
maceuticals. Secondary objective was to potentially identify predictors for access 
delay. MethOds: All AMNOG assessment procedures that were completed at the 
level of the joint federal committee (G-BA) by May 15 2013 were included (web-
site www.g-ba.de). Time delay to dossier submission was calculated between the 
approval date of the European Medicines Agency (EMA) and the mandatory AMNOG 
dossier submission date. Submission date usually occurs when pharmaceuticals are 
made available and is decided upon by the manufacturer. We also included in the 
analysis the ordinal level classification and evidence certainty level for each product 
as assessed by Institute for Quality and Efficiency in Health Care (IQWiG) and G-BA 
as well as the ATC code. Results: In n= 17 (49%) of N= 35 investigated pharmaceu-
ticals a small time delay greater than 1.1 months (which is usually feasible) after 
EMA approval was observed, but only 20% had a delay > 2 months. A negative cor-
relation existed between the amount of time delay to dossier submission and the 
benefit level outcome as assessed by IQWIG (r= -0.258, n.s.) and the final result by 
G-BA (r= -0.484, p= 0.003). Benefit assessment outcomes between IQWiG and G-BA 
were correlated moderately with r= 0.442 (p< 0.008). For both, IQWiG (r= 0.841) and 
G-BA (r= 0.773) certainty of evidence correlated highly with the benefit level out-
come. cOnclusiOns: This analysis highlights the impact of AMNOG on the market 
access of pharmaceuticals in Germany. Overall, only small time delays existed for 
most products. Time delay in market access correlated significantly with a nega-
tive assessment of additional benefit by G-BA. Evidence certainty clearly correlated 
with benefit outcomes.
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Objectives: In Scotland, drug reimbursement is predominantly based on cost-
effectiveness in contrast to the corresponding German AMNOG process. The study 
compares the reimbursement and pricing process in Germany (AMNOG), as reformed 
in 2011, and Scotland (SMC) based on reimbursement assessments. MethOds: All 
AMNOG and SMC appraisal decisions made in 2011-2012 were identified. Matching 
AMNOG-SMC cases were found and compared in terms of final appraisal decision 
and rationale. Results: For 2011-2012, forty-one AMNOG cases over 60 subgroups 
and 193 SMC cases were identified; twenty five matching cases were compared 
as these were assessed by both organizations. Regarding these 25 cases, AMNOG 
deemed ten cases demonstrated no additional benefit, in two cases the additional 
benefit was unquantifiable, slight benefit was acknowledged in seven cases and 
in six there were significant benefits. Based on the benefit assessment the negoti-
ated price rebates ranged from 4.7% to 70.7% based on manufacturer set price. No 
restrictions to subgroups were opposed to any reimbursement decision. The SMC 
reimbursed 18 products (72%), of which four were restricted to a certain population 
due to cost-effectiveness. SMC rejected 7 cases (28%) based on weak economic evi-
Objectives: To investigate the problem of pricing and reimbursement of pharma-
ceuticals in Iran. A large amount of country’s Health care expenditures, including 
insurance organizations’ expenses, are spent for pharmaceutical products. However, 
the high amount of capital spent by the users for purchasing pharmaceuticals 
indicates a serious flaw in the system. As will be shown, this flaw is due to the struc-
tures, policies, and regulations of Iranian medical insurance system. MethOds: 
This is a descriptive study and, therefore, ethnographic site and fieldwork were used 
as the main source of information. Furthermore, information on the Internet and 
several Iranian online databases has been used for comparison purposes. Results: 
Ministry of Health and Medical Education (MOHME) is the main responsible body 
for pharmaceuticals in Iran. However, different government organizations such 
as Ministry of Commerce, the Central Bank of Iran, and National Industries 
Organizations are involved in policy-making in this sector. MOHME decides how 
to allocate governmental supports and foreign currency quotas, to various related 
industries. This is done due to the fact that MOHME decides which pharmaceuti-
cals should be covered and distributed in the country. However, prices are set by 
insurance organizations due to their bargaining power over MOHME. Insurance 
companies pay approximately 70-90% of the final price of a product. However, for 
purchasing expensive products, confirmation from insurance companies is needed. 
The reimbursed price is set at the level of the lowest priced equivalent on the mar-
ket. cOnclusiOns: These flaws and loopholes arise because of system’s negligence 
on research and development methods and, therefore, lack of standard regulations 
on reimbursement decisions and priority settings. Inflexible profit margins for dif-
ferent products with different unit costs, incomplete support for vulnerable groups 
and patients with chronic diseases, and absence of rational pharmaceutical usage 
campaigns can be named as other major problems.
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Objectives: Personalized health care (PHC) is a treatment model that customizes 
health care based on biomarker-based prediction of likely response. It is increas-
ingly being prioritized by politicians and payers—one recent example is the pub-
lished strategy plan by the German Federal Ministry of Education and Research. 
A key policy question remains whether health care systems and health tech-
nology assessment (HTA) bodies are adequately prepared evaluating these new 
treatment options. MethOds: Existing HTA evaluation methods for therapies in 
France, Germany, and the UK were reviewed with respect to the applicability to 
PHC products based on information provided by decision-making bodies and the 
literature. Results: Current HTA evaluation methods being applied to medical 
therapies, in general, need to be modified when applied to PHC. For example, tra-
ditional benefit evaluations that require randomized clinical trials are standard 
but cannot always be fulfilled in PHC. Furthermore, combined benefit assessments 
for typical PHC treatment—e.g., a pharmaceutical combined with a diagnostic 
test—lack experience about appropriate evaluation methods to use. Today, decison 
makers and manufacturers rarely make use of the opportunity to re-assess or for 
joint evidence generation. Finally, reimbursement for PHC is inflexible and does 
not fully reflect the value of targeting, including the reduction in uncertainty and 
greater appropriate use. Among these three, the UK seems the most open to PHC 
funding. HTA in France and Germany does not recognize the special economic and 
evidence features of PHC, though the French system is more open to innovative 
market access. cOnclusiOns: If the largest EU health care systems are to secure 
the full benefits of PHC, they will need to provide for full and flexible reimbursement 
for innovative technologies and services based on value. Currently, the importance 
of PHC by health care politicians is not being reflected in the evaluation tools or 
reimbursement methods being applied.
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Objectives: To analyse trends in reimbursement in Ireland to help in the planning 
of HTAs from an industry perspective. MethOds: A database of all NCPE deci-
sions and reimbursement for drugs from 2006 to April 2013 was developed from 
publically available NCPE reports and HSE websites. A descriptive analysis of the 
database was undertaken. Results: From 2006 to April 2013 37% of drugs were 
reimbursed without a HTA and 63% were recommended for HTA (N= 126). There 
were three HTAs undertaken in 2006 compared to 26 in 2012. High Tech (HT) drugs 
were more likely to attract a HTA compared to General Medical Services (GMS) drugs 
(83% vs. 51%). Of the HTAs completed, 57% resulted in a positive reimbursement 
recommendation within a median time from HTA submission to reimbursement 
of 7.9 months (min 3.9, max 16.3). The median time was 7.1 and 9.8 months for 
GMS and HT drugs respectively. Dominance almost perfectly predicted reimburse-
ment; 83% reimbursed. Of the ICERs in the north-east quadrant, 54% resulted in 
a positive reimbursement recommendation (average ICER around € 60,000/QALY). 
The cost per QALY for those not reimbursed in this quadrant was almost twice this 
at around € 110,000. Finally, the average probability of cost effectiveness for reim-
bursed and non-reimbursed drugs were 60% and 30% respectively. cOnclusiOns: 
Companies can expect more requests for HTAs especially for HT drugs. When HTAs 
are requested the probability of success is around 60% with an expected timeline 
of 8 months from submission to launch. Budget impact does have an important 
role to play as dominance is a strong predictor of reimbursement. The average cost 
per QALY for reimbursed drugs is above the € 45,000/QALY threshold but does not 
